- Previous Close
228.10 - Open
227.41 - Bid --
- Ask --
- Day's Range
213.41 - 227.41 - 52 Week Range
87.50 - 243.99 - Volume
4,849,586 - Avg. Volume
8,936,590 - Market Cap (intraday)
283.909B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
796.70 - EPS (TTM)
0.27 - Earnings Date --
- Forward Dividend & Yield 0.11 (0.05%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
--
Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.
www.piramalpharma.com6,719
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: PPLPHARMA.NS
View MoreResearch Reports: PPLPHARMA.NS
View MorePerformance Overview: PPLPHARMA.NS
Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PPLPHARMA.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PPLPHARMA.NS
View MoreValuation Measures
Market Cap
300.99B
Enterprise Value
343.05B
Trailing P/E
814.64
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.60
Price/Book (mrq)
3.81
Enterprise Value/Revenue
4.13
Enterprise Value/EBITDA
24.02
Financial Highlights
Profitability and Income Statement
Profit Margin
0.33%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
83.73B
Net Income Avi to Common (ttm)
277.6M
Diluted EPS (ttm)
0.27
Balance Sheet and Cash Flow
Total Cash (mrq)
5.02B
Total Debt/Equity (mrq)
59.54%
Levered Free Cash Flow (ttm)
--